The lancet oncology
-
The lancet oncology · Nov 2020
Randomized Controlled Trial Multicenter StudyTazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Activating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patients with follicular lymphoma. ⋯ Epizyme.
-
The lancet oncology · Nov 2020
Meta AnalysisGamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis.
Gamma knife radiosurgery is regarded as the gold-standard stereotactic radiosurgery modality for the treatment of intracranial tumours, and its use has been expanded for the treatment of intraocular malignancies. The aim of this study was to systematically evaluate the efficacy, outcomes, and complications of gamma knife radiosurgery for uveal melanomas and metastases. ⋯ The Rhodes Trust and the Howard Brain Sciences Foundation.
-
The lancet oncology · Nov 2020
Randomized Controlled Trial Multicenter StudyTazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinical activity and safety of tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma. ⋯ Epizyme.